Company Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.
The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jul 12, 2017 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Dwight H. Egan |
Contact Details
Address: 4049 South Highland Drive Salt Lake City, Utah 84124 United States | |
| Phone | (801) 278-9769 |
| Website | codiagnostics.com |
Stock Details
| Ticker Symbol | CODX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001692415 |
| CUSIP Number | 189763105 |
| ISIN Number | US1897631057 |
| Employer ID | 46-2609396 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dwight H. Egan | Chairman and Chief Executive Officer |
| Brian L. Brown CPA | Chief Financial Officer and Company Secretary |
| Richard David Abbott | President |
| Dr. Brent C. Satterfield Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| David Nielsen | Chief Operating Officer |
| Dan Bohrer CPA | Vice President of Finance and Accounting |
| Christopher Thurston | Chief Technology Officer |
| Dr. Mark Poritz Ph.D. | Chief Scientific Officer |
| Andrew Benson | Head of Investor Relations |
| Dr. Mayuranki Almaula | Senior Vice President of Overseas Operations and Strategic Alliances |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 14, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |